Procaps Group (Procaps Group) Loans Receivable : $0.0 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Loans Receivable?

Procaps Group's Loans Receivable for the quarter that ended in Sep. 2023 was $0.0 Mil.

Procaps Group Loans Receivable Historical Data

The historical data trend for Procaps Group's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Loans Receivable Chart

Procaps Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Loans Receivable

Procaps Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Loans Receivable	Get a 7-Day Free Trial											-	-	-	-	-

Procaps Group Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Procaps Group Loans Receivable Related Terms

Thank you for viewing the detailed overview of Procaps Group's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group (Procaps Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371